Mechanisms of Atrial Pathoelectrophysiology in HCM

NCT07454135 | Not Yet Recruiting

• 1 other identifier: 339394
• Study Type: observational
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to learn why atrial fibrillation (AF), a type of irregular heartbeat, happens more often and is harder to treat in people with hypertrophic cardiomyopathy (HCM). HCM is an inherited condition where the heart muscle is thicker than usual. Researchers will study electrical signals from the heart and advanced heart imaging. By doing this, they hope to better understand how AF behaves in people with HCM and why treatments may not work as well for them. The information from this study may help improve future treatments for people who have both HCM and AF.

Conditions

Atrial Fibrillation (AF); Hypertrophic Cardiomyopathy (HCM)

Keywords

hypertrophic cardiomyopathy; atrial fibrillation

Outcome Measures

Primary Outcomes (1)

• Changes in electrophysiological properties of the atria in patients with HCM and AF compared to patients with AF and structurally normal hearts

  At the time of the clinical ablation procedure

Secondary Outcomes (2)

• Correlatation between the electrophysiological changes in the atria with directly measured left atrial pressure, extent of late gadolinium enhancement and ventricular extracellular volume .

  At the time of clinical ablation procedure

• Response to various ablation strategies applied in patient specific computational models.

  Based on measurements taken during the clinical ablation procedure

Study Arms (1)

Patients with HCM and AF

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with hypertrophic cardiomyopathy and atrial fibrillation requiring atrial fibrillation ablation.

You may qualify if:

• Paroxysmal or persistent atrial fibrillation
• Diagnosis of hypertrophic cardiomyopathy
• Patient planning to proceed to atrial fibrillation ablation following clinical consultation
• Age 18-80 years
• Able and willing to provide written informed consent
• Able and willing to comply with study follow up requirements

You may not qualify if:

• Any clinical contra-indication to ablation
• Any disease limiting life expectancy to \<1 year
• Potential participant currently pregnant or breast feeding
• Contraindication to MRI including renal dysfunction (eGFR\<30ml/min)
• Unable to understand verbal or written explanations given in English

Sponsors & Collaborators

• Guy's and St Thomas' NHS Foundation Trust: lead
• King's College London: collaborator

Study Sites (1)

Guy's and St Thomas' NHS Foundation Trust

London, United Kingdom

Location

MeSH Terms

Conditions

Cardiomyopathy, Hypertrophic; Atrial Fibrillation

Condition Hierarchy (Ancestors)

Cardiomyopathies; Heart Diseases; Cardiovascular Diseases; Aortic Stenosis, Subvalvular; Aortic Valve Stenosis; Aortic Valve Disease; Heart Valve Diseases; Arrhythmias, Cardiac; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 2, 2026
• First Posted: March 6, 2026
• Study Start: March 8, 2026
• Primary Completion (Estimated): September 30, 2027
• Study Completion (Estimated): September 30, 2027
• Last Updated: March 6, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

GB (1)